New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
08:06 EDTHRTXHeron selects HTX-011 as lead product for post-surgical pain program
Heron Therapeutics announced that it has selected HTX-011, a unique combination product utilizing its proprietary Biochronomer polymer-based drug delivery platform, as the lead product candidate for its post-surgical pain program. HTX-011 is designed to slowly release the local analgesic agent bupivacaine and the NSAID meloxicam locally at the site of the surgery over 3-5 days. By slowly delivering these agents directly to the location of the pain, lower doses can be used, which should result in greater efficacy with a lower risk of side effects. In a validated animal model, HTX-011 significantly reduced mean pain intensity compared to the current market leader, Exparel for up to 72 hours following surgery. Based on these results, the company has initiated a Phase 1 enabling toxicology study, to be followed by the initiation of a Phase 1 study in the fall.
News For HRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
08:41 EDTHRTXHeron Therapeutics price target raised to $33 from $25 at JMP Securities
After meeting with Heron's management, JMP Securities believes that momentum is building for the company's acute pain program. The firm expects data slated to be announced next quarter to eliminate the program's risk. It keeps an Outperform rating on the shares.
June 26, 2015
10:00 EDTHRTXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:43 EDTHRTXHeron Therapeutics initiated with an Outperform at Cowen
Target $40.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use